The high-end vaccine subsidiary's next-generation polyvalent enterovirus vaccine development plan has initiated a dual-track strategy of international cooperation and domestic process development. Internationally, it has entered into a strategic cooperation with Charles River Laboratories in the United States. Domestically, it has signed cooperation agreements with Taiwan Biopharm and Qihong Biotech.